Biogen has completed its acquisition of Apellis Pharmaceuticals for approximately $5.3 billion, funded in part by a new $2 billion term loan facility. The transaction includes contingent value rights (CVRs) that could pay up to $4.00 per share based on future SYFOVRE sales milestones. This acquisition expands Biogen's product portfolio but increases its leverage and introduces performance-linked contingent liabilities.
